A Variable Region in GP4 of European-Type Porcine Reproductive and Respiratory Syndrome Virus Induces Neutralizing Antibodies Against Homologous But Not Heterologous Virus Strains

Merijn Vanhee,1 Sarah Costers,1 Wander Van Breedam,1 Marc F. Geldhof,1 Jan Van Doorselaere,2 and Hans J. Nauwynck1

Abstract

Porcine reproductive and respiratory syndrome virus (PRRSV) can induce severe reproductive failure in sows, and is involved in the porcine respiratory disease complex. The glycoprotein GP4 of the European prototype PRRSV strain Lelystad virus (LV) contains a linear neutralizing epitope that is located in a highly variable region. The current study aimed to evaluate the antibody response against this and other epitopes on GP4 to infection of pigs with European-type PRRSV. It was shown that three virus strains, differing in the region that corresponds to the neutralizing epitope on GP4 of LV, strongly induce antibodies against this area. Antibodies against the epitopes of the different virus strains were purified from polyclonal swine sera, and used in virus-neutralization tests on primary alveolar macrophages. This revealed that antibodies against the variable region in GP4 of different virus strains are able to neutralize infection with homologous but not heterologous virus strains.

Introduction

**Porcine reproductive and respiratory syndrome virus** (PRRSV) is an enveloped positive single-stranded RNA virus that belongs to the family Arteriviridae in the order Nidovirales (18,49). PRRSV can cause severe reproductive failure in sows, characterized by late-term abortion, early farrowing, stillbirth, and the birth of weak piglets (5,6,41,49). Furthermore, the virus is associated with the porcine respiratory disease complex, causing respiratory disease in combination with secondary infections (42,44). Alveolar macrophages are considered the primary *in vivo* target cells for PRRSV, and it has been shown that the virus requires the cell-specific entry-mediators sialoadhesin and CD163 to establish efficient infection in those cells (2,14,43,46). *In vitro*, the virus can be grown in primary alveolar macrophages (PAM), and African green monkey kidney cell lines such as Marc-145, in which it uses an alternative receptor mechanism (13,19,20). The PRRSV virion consists of a nucleocapsid core, composed by the N protein that encapsulates the viral genome. The nucleocapsid is surrounded by a lipid envelope, in which six structural proteins are embedded. The membrane protein M and glycoprotein GP5 represent the majority of envelope proteins and are present as disulfide-linked heterodimers, while glycoproteins GP2, GP3, and GP4, together with the non-glycosylated protein E, are minor envelope proteins (8,26–28,52). PRRSV shows extensive genetic variability, and virus strains are classified into European (EU) type strains and North American (NA) type strains (1,39). In addition, a high variability exists within each genotype, and EU-type strains can be further subdivided into three subtypes (12,15,30,40). Upon infection with PRRSV, virus-specific antibodies appear within 1–2 wk, but virus-neutralizing antibodies are generally not detected earlier than 3–5 wk post-infection in small amounts, and by that time an extensive viremia has already taken place (11,22,47,55). Nevertheless, virus-neutralizing antibodies are able to inhibit replication of virus in PAM, and the presence of sufficiently high titers in serum before infection offers *in vivo* protection against viremia, virus replication in lungs, and transplacental spread of the virus (10,24,25). The identification of viral proteins and epitopes that are able to induce virus-neutralizing antibodies is thus a main topic of interest regarding the development of novel PRRSV vaccines. A neutralizing epitope on GP5 of NA-type PRRSV has been

---

1Laboratory of Virology, Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

2Department of Health Care and Biotechnology, KATHO Catholic University College of South-West Flanders, Roeselare, Belgium.
identified by the use of mouse monoclonal antibodies (mAbs), and the appearance of serum antibodies in pigs against GP5, and against this epitope in particular, correlates with virus neutralization. This has led to the assumption that GP5 of NA-type PRRSV is the main target for virus-neutralizing antibodies (17,35,37). A neutralizing epitope has also been identified on GP5 of an EU-type PRRSV strain. This epitope is situated upstream of the neutralizing epitope on GP5 of NA-type strains; however, only a very narrow range of virus strains that contain a rare mutation in the putative N-terminal signal peptide of GP5 are susceptible to neutralization by mAbs against this epitope, questioning the relevance of this epitope in vivo (48,50,51). On GP4 of the prototype EU strain Lelystad virus (LV), an epitope has been identified that is a target for virus-neutralizing mAbs in continuous cell lines as well as in PAM (7,28,45). This epitope is immunogenic in pigs, but shows a huge genetic variability, and antibodies against this epitope show little or no reactivity with other EU-type PRRSV strains (12,28,34). Although it is known that pigs produce antibodies against this epitope on GP4 upon infection with different EU-type PRRSV strains, no detailed information is available concerning the kinetics of the antibody response against this or other epitopes on GP4. Moreover, it remains unclear whether the hypervariable region corresponding to the neutralizing epitope on GP4 of LV also serves as a target for virus-neutralizing antibodies on PRRSV isolates other than LV. The aim of the current study was to investigate the antibody response against GP4 upon infection of pigs with different EU-type PRRSV strains. The kinetics of the GP4-specific antibody response after initial infection with LV in naive piglets was determined. Subsequently, linear epitopes on GP4 that are targeted by porcine serum antibodies were identified, and it was determined whether antibodies against these epitopes were able to reduce PRRSV-replication in macrophages. Finally, the influence of genetic variability on induction of antibodies and recognition of epitopes was determined by the use of two recent EU-type field virus strains that differ from LV and from each other in the neutralizing epitope on GP4.

Materials and Methods

Cell cultures

Primary porcine alveolar macrophages (PAM) were obtained from 4-wk-old conventional Belgian Landrace pigs from a PRRSV-negative herd as previously described, and cultivated in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 1% non-essential amino acids, and 1 mM sodium pyruvate (49). Hek-293T cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM), with 5% FCS, 2 mM L-glutamine, and 1 mM sodium pyruvate. Marc-145 cells were cultivated in minimum essential medium (MEM), with 5% FCS, and 2 mM L-glutamine. All cells were cultivated in their respective media, supplemented with a mixture of antibiotics at 37°C in a humidified atmosphere with 5% CO2.

Viruses

PRRSV strain 07V063 was isolated from an aborted fetus, derived from a Belgian farm during an outbreak of PRRSV-associated reproductive disorders. PRRSV strain 08V204 was isolated from a Belgian farm from serum of 8-wk old healthy piglets that showed PRRSV-specific antibodies. For inoculation of piglets, the prototype EU-type PRRSV strain LV and field virus strains 07V063 and 08V204 were propagated in PAM, derived from gnotobiotic piglets (LV: fifth passage, 07V063: second passage, 08V204: third passage) (49). For a single-replication virus-neutralization test on PAM, virus was propagated in PAM from conventional pigs (LV: 13th passage, 07V063: second passage, 08V204: third passage). For a classical seroneutralization test on Marc-145 cells, virus was propagated in Marc-145 cells (LV: fourth passage, 07V063: second passage, 08V204: third passage).

ORF4 sequencing

The ORF4 sequences of all virus stocks used in this study were determined. RNA was extracted using an RNeasy Protect Mini Kit (Qiagen Inc., Valencia, CA) according to the manufacturer’s protocol. Total RNA was reverse transcribed using a multiprime cDNA synthesis kit (Applied Biosystems, Foster City, CA). A region containing the complete ORF4 sequence was amplified using Taq Polymerase (Invitrogen Corp., Carlsbad, CA), and the following primers: forward primer 5’-cggcccaacctcagcag-3’, recognizing the complement sequence of nucleotides 12756–12775 upstream of ORF4 in LV (5’-ccgaggctctcccggag-3’), and reverse primer 5’-catt cagcgtagttggtggaatg-3’, recognizing nucleotides 13631–13653 downstream of ORF4 in LV (5’-cgggaggctctcccggag-3’). This resulted in an 898-bp fragment for LV and 07V063, and a 866-bp fragment for 08V204. PCR products were treated with Exonuclease I and Antarctic Phosphatase (New England Biolabs, Ipswich, MA), and used directly for cycle sequencing with a Big Dye Terminator Cycle sequencing kit V1.1 (Applied Biosystems), and the aforementioned primers. Cycle sequencing reaction products were purified by ethanol precipitation and separated on an ABI Genetic 310 (Applied Biosystems). The ORF4 sequences of 07V063 and 08V204 were submitted to Genbank (accession numbers GU737264 and GU737266). The ORF4 sequence of LV was 100% identical to the one that was described earlier (Genbank accession number M96262). No differences in ORF4 sequence were observed between the viral passages on PAM, as well as Marc-145 cells, for any of the virus strains.

Experimental inoculation of animals, serum collection and detection of viremia and virus-specific and virus-neutralizing antibodies

Nineteen piglets were derived from a PRRSV-negative farm and their seronegative status was confirmed by immunoperoxidase monolayer assay (IPMA). Two groups of six and one group of seven piglets were inoculated intranasally at the age of 14 wk with 10⁶ TCID₅₀ of the PRRSV strain LV, 07V063, or 08V204, respectively. Sera were collected at different time points between 3 and 44 d post-infection (p.i.) for LV-infected animals, and just at 44 days pi for 07V063-and 08V204-infected animals. Virus titers were determined by titration on PAM, followed by immunoperoxidase staining with mAb P3/27 against the nucleoprotein (22,50). Sera for antibody detection were heat inactivated at 56°C for 30 min. PRRSV-specific antibodies were detected by IPMA, and virus-neutralizing antibodies by classical seroneutralization testing on Marc-145 cells as previously described, with the respective virus strain as antigen (22,47).
Detection of GP4-specific serum antibodies

Synthesis of an ORF4 DNA construct. RNA was extracted from LV and reverse transcribed using Superscript RT (Invitrogen) with oligo(dT) primers. The cDNA was used for PCR with Platinum Pfx DNA polymerase (Invitrogen) and the following primers: forward primer 5’-gtctagccacctgatcgagctggg-3’, and reverse primer 5’-atctagccacctgatcgagctggg-3’. The ORF4 plasmid DNA, using calcium phosphate precipitation (4). At 48 h post-transfection, the cells were fixed by air drying and stored at -20°C. Expression of GP4 was verified by immunoperoxidase staining with mAb XVI11C/5F10 against GP4 of LV (7).

Transient transfection of Hek-293T cells. Hek-293T cells were seeded in a 96-well plate at a concentration of 25,000 cells per well, and incubated for 24 h before transfection. The cells were transfected with 1.5 µg per well of the LV ORF4 plasmid DNA, using calcium phosphate precipitation (4). At 48 h post-transfection, the cells were fixed by air drying and stored at -20°C. Expression of GP4 was verified by immunoperoxidase staining with mAb XVI11C/5F10 against GP4 of LV (7).

IPMA on GP4-expressing cells. GP4-specific serum antibody titers were determined by IPMA on GP4-expressing Hek-293T cells. The cells were thawed, fixed with 4% paraformaldehyde for 10 min at room temperature, washed with PBS, and treated with 1% H2O2 in methanol for 5 min. A 1:4 dilution series of heat-inactivated serum was prepared in PBS with 10% negative goat serum and 1% Tween-80. The reaction substrate solution of 3-amino-9-ethylcarbazole (AEC) in PBS, and treated with 1% H2O2 in methanol for 5 min. A 1:4 dilution series of heat-inactivated serum was prepared in PBS with 10% negative goat serum and 1% Tween-80, and incubated for 1 h at 37°C on the cells. The cells were washed with PBS with 1% Tween-80, and incubated for 1 h at 37°C with an optimal dilution of peroxidase-conjugated goat-anti-swine polyclonal antibodies (Jackson ImmunoResearch West Grove, PA). The cells were washed and incubated with a substrate solution of 3-amino-9-ethylcarbazole (AEC) in 0.05 M acetate buffer (pH 5) with 0.05% H2O2. The reaction was blocked by replacing the substrate with acetate buffer. The GP4-specific IPMA titer was defined as the reciprocal value of the highest serum dilution that showed staining of GP4-expressing cells.

Pepscan analysis

Epitope mapping was performed by pepscan analysis, using sets of overlapping peptides in a peptide ELISA (16). Sets of 44 overlapping dodecapeptides with an offset of 4 and an overlap of 8 were synthesized by solid-phase synthesis, based on the amino acid (aa) sequences of GP4 of virus strains LV, 07V063, and 08V204. All peptides were provided by JPT Peptide Technologies, GmbH (Berlin, Germany), as a set of BioTides that contained a hydrophilic spacer with a biotin molecule at the C-terminal end. Streptavidin-coated 96-well plates (VWR International, LLC) were coated for 1 h with 0.1 µg of biotinylated peptide in PBS with 0.5% Tween-20, washed, and blocked overnight with blocking buffer containing 1% bovine serum albumin (R&D Systems, Inc., Minneapolis, MN), and 0.5% Tween-20. Serum (1:100) or epitope-specific serum antibodies (100 µg/mL) were diluted in blocking buffer and incubated for 1 h on the peptide-coated plates, followed by washing and incubation with an optimal dilution of peroxidase-conjugated goat-anti-swine polyclonal antibodies. The plates were washed and developed with a substrate solution of tetramethylbenzidine and H2O2 (R&D Systems). The reaction was stopped after 10 min with 1 M H2SO4, and the optical density (OD) at 450 nm was measured. All wash steps were performed with PBS with 0.5% Tween-20, and all incubation steps were carried out at room temperature. Background OD levels were determined by including serum or protein A purified serum antibodies from a serologically PRRSV-negative pig. Specific signals within a pepscan analysis were determined as follows. For each separate peptide, the OD value obtained with the negative control sample was expressed relative to the OD value obtained with the negative control sample (% sample/negative). The mean percentage sample/negative over all 44 peptides was calculated. If the percentage sample/negative at a certain peptide was more than two times the mean percentage sample/negative over all peptides, the signal was considered to be specific.

Purification of peptide-specific serum antibodies

We had 12-mer peptides with purity >80% synthesized by JPT Peptide Technologies. For each epitope, 1 mg peptide was covalently coupled to an N-hydroxysuccinimide-activated sepharose column (HiTrap NHS-activated HP; GE Healthcare, Piscataway, NJ), following the manufacturer’s instructions, and a blank purification procedure was performed prior to use. The serum was clarified by centrifugation and filtration, inactivated for 30 min at 56°C, and the pH was adjusted with 200 mM Na2HPO4 (pH 7.0). After equilibration of the column with 20 mM Na2HPO4 (pH 7.0), serum was run over it and the column was subsequently washed with 20 mM Na2HPO4 buffer. When no more protein could be detected by spectrophotometry at 278 nm in the wash fractions, peptide-specific antibodies were eluted from the column with 0.1 M glycine (pH 2.7), and collected in 1 M Tris (pH 8.0). Elution fractions that contained protein, as measured by spectrophotometry at 278 nm, were pooled, dia lysed against PBS, and stored at -70°C. The specificity of the obtained antibodies was evaluated by peptide ELISA as described above.

Single replication virus-neutralization test on PAM

Twofold serial dilutions of epitope-specific serum antibodies in PBS (1000–32 µg/mL) were mixed with equal volumes of PAM-grown virus with a titer of 2×10⁶ TCID₅₀/mL, resulting in 10⁵ TCID₅₀/mL virus, and an antibody concentration range of 500–16 µg/mL. Protein A purified antibodies from a serologically PRRSV-negative pig were included as mock antibody condition. Virus-antibody mixtures were incubated for 1 h at 37°C, and then added to a 96-well plate (100 µL/well), containing PAM at a concentration of 10⁵ cells/well, that were cultivated for 48 h prior to use. After 1 h of incubation, the inoculum was removed and replaced by medium, after which the cells were further incubated for another 10 h, fixed by
dryng, and stored at −20 °C. The cells were stained for PRRSV infection with mAb P3/27 against the nucleocapsid protein of PRRSV and peroxidase conjugated goat-anti-mouse polyclonal antibodies (Dako Denmark A/S, Glostrup, Denmark), followed by development with AEC. The number of infected cells in each well was counted in three fields at 200× magnification, and expressed relative (%) to the mean number of infected cells for all mock conditions within the same experiment. The experiments were performed in triplicate. The relative percentage of infected cells was analyzed by two-way analysis of variance, followed by Bonferroni post-tests to determine statistically significant differences between treatment and mock antibody conditions for a given antibody concentration. Statistical analysis was performed using GraphPad Prism version 5.0a software (GraphPad Software, San Diego, CA).

Results

Viremia, virus-specific, and virus-neutralizing antibody response upon infection with LV

Six piglets were inoculated with the European prototype PRRSV strain LV, and serum virus titers, virus-specific antibody titers, and virus-neutralizing antibody titers were determined. All pigs showed viremia, starting from 3 d p.i. until 3–4 wk p.i. (Table 1). Virus-specific antibodies, as measured by IPMA, appeared at 1 (n=2) or 2 (n=4) weeks p.i., and maximum antibody titers varied between 11.3 and 13.3 log2 (Fig. 1A). Virus-neutralizing antibodies, as measured by classical seroneutralization testing on Marc-145 cells, were not detected earlier than 3 (n=1), 4 (n=2), 5 (n=2), or 6 (n=1) weeks p.i., with maximum titers no higher than 3.6 log₂ (Fig. 1B).

GP4-specific antibody response upon infection with LV

Antibodies against GP4 were detected by IPMA on GP4-expressing Hek-293T cells in serum of all LV-infected pigs. GP4-specific antibodies appeared at two (n=1), three (n=3), or four (n=4) weeks p.i., and reached maximum titers between 7.3 and 11.3 log₂ (Fig. 1C).

Epitope-specificity of GP4-specific serum antibodies in LV-infected pigs

To discover linear epitopes against which the GP4-specific serum antibodies of LV-infected pigs were directed, a pepscan analysis was performed with sera collected between 7 and 44 d p.i. Sera of all six pigs contained antibodies directed against overlapping peptides 14, 15, and 16. The central peptide 15, with sequence GVSAAQEKFSG at aa position 57–68, was considered the core of this epitope. Antibodies against this epitope were detected starting from 2 wk p.i. for pig 3, and from 3 wk p.i. for the other pigs. An additional epitope, defined by peptides 22 and 23, was recognized by serum from pigs 2 and 3, starting from 4 wk p.i. Peptide 22, with sequence ITANVTDESGLY at aa position 85–96, was considered the core of this epitope, because signals were systematically higher at peptide 22 than at peptide 23. Fig. 2 represents an example of a pepscan profile of sera that recognizes only peptides 14–16 (A), or both peptides 14–16 and 22–23 (B).

Virus-neutralization by antibodies against epitopes on GP4 of LV

To evaluate the ability of serum antibodies against the identified epitopes to inhibit virus replication in vitro, antibodies against peptide 15 (GVSAAQEKFSG) or peptide 22 (ITANVTDESGLY) were purified from polyclonal serum by peptide affinity chromatography. Pepscan analysis revealed that antibodies purified against GVSAAQEKFSG recognized peptides 14, 15, and 16, while antibodies purified against ITANVTDESGLY recognized peptides 22 and 23. Subsequently, the epitope-specific antibodies were used in a single replication virus-neutralization test with LV on PAM. Antibodies against GVSAAQEKFSG were able to reduce infection of LV in PAM in a concentration-dependent manner (Fig. 3A). The number of infected cells was significantly reduced (p < 0.01), by more than 50% by antibody concentrations of 125 μg/mL or higher, compared to infection in the presence of similar concentrations of mock antibodies. Antibodies against ITANVTDESGLY did not reduce replication of LV in PAM in any concentration up to 500 μg/mL (Fig. 3B).

ORF4 sequence analysis of PRRSV strains 07V063 and 08V204

To determine whether the GP4-specific antibody response is similar for EU-type virus strains other than LV, two Belgian PRRSV field isolates were selected: 07V063 and 08V204. ORF4 sequence analysis of these strains revealed that 07V063 shows 87% aa homology with LV in GP4, while 08V204 shows 85% aa homology with LV in GP4. Alignment of the GP4 aa sequences of LV, 07V063, and 08V204 revealed that the majority of the variation is located between aa positions 46 and 70 (Fig. 4). Out of 12 aa that determine the neutral-

Table 1. Serum Virus Titers Upon Infection with Lelystad Virus

<table>
<thead>
<tr>
<th>Pig no.</th>
<th>Days post-inoculation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>&lt;0.96</td>
</tr>
<tr>
<td>2</td>
<td>&lt;0.96</td>
</tr>
<tr>
<td>3</td>
<td>&lt;0.96</td>
</tr>
<tr>
<td>4</td>
<td>&lt;0.96</td>
</tr>
<tr>
<td>5</td>
<td>&lt;0.96</td>
</tr>
<tr>
<td>6</td>
<td>&lt;0.96</td>
</tr>
</tbody>
</table>

Six pigs were inoculated intranasally with 10⁶ TCID₅₀ of Lelystad virus and bled at different time points post-infection. Serum virus titers (log₁₀ TCID₅₀/mL) were determined by titration on primary alveolar macrophages.
izing epitope of LV (aa 57–68), only five are conserved between LV and 07V063, and no more than two between LV and 08V204, and a deletion of 4 aa is present in the 08V204 sequence. Moreover, 07V063 and 08V204 only share three common aa in this region, and except for the glutamine at position 62, no aa are conserved over the three virus strains. In the non-neutralizing epitope at position 85–96, all but one or two aa are conserved between LV and 07V063 or 08V204, respectively.

Linear serum antibody epitopes on GP4 of 07V063 and 08V204

Six and seven pigs were infected with 07V063 or 08V204, respectively, and all pigs showed viremia and a virus-specific antibody response (data not shown). To determine the linear epitopes on GP4 against which serum antibodies were directed, a homologous pepscan analysis was performed with sera collected at 44 days p.i. All but one pig infected with virus strain 07V063 possessed antibodies against peptides 15 and 16, with the highest signals at peptide 15 (RVTAAQGRIYTR, aa position 57–68). Two pigs had antibodies against peptides 22 and 23, with the highest signals at peptide 22  (VTANVTDESILY, aa position 85–96). Similarly, all seven pigs infected with virus strain 08V204 had antibodies against peptides 14 and 15, with the highest signals at peptide 15 (RTNTTQGKVPSQ, aa position 57–68), and three of them had antibodies against peptides 21 and 22, with the highest signals at peptide 21 (MTANVTDKSYLY, aa position 81–92) (Fig. 4).

Virus-neutralization by antibodies against epitopes 57–68 on GP4 of 07V063 and 08V204

Antibodies against aa sequences RVTAAQGRIYTR or RTNTTQGKVPSQ were purified from polyclonal serum of pigs infected with PRRSV strain 07V063 or 08V204, respectively, and their specificity was verified by pepscan analysis on homologous GP4. Antibodies against epitope RVTAAQGRIYTR on GP4 of 07V063 reduced replication of the homologous virus strain in PAM in a dose-dependent manner. The number of infected cells was significantly reduced ($p < 0.01$), by more than 50%, with antibody concentrations of 125 μg/mL or higher, compared to infection in the presence of mock antibodies (Fig. 5A). Similarly, antibodies against epitope RTNTTQGKVPSQ of 08V204 reduced the number of cells infected with the homologous virus in a dose-dependent manner, and here the lowest antibody concentration that gave a significant reduction ($p < 0.01$) of more than 50% was 31 μg/mL ($p < 0.01$) (Fig. 5B).

Cross-recognition and cross-neutralization by antibodies against the neutralizing epitope on GP4 of LV, 07V063, and 08V204

Sera derived from LV-, 07V063-, or 08V204-infected pigs at 44 d p.i. were tested in a pepscan analysis on GP4 of the heterologous virus strains (data not shown). None of the sera that reacted with aa position 57–68 in the homologous pepscan recognized this region in the heterologous pepscans for each virus strain. Sera of LV-infected pigs that reacted with aa position 87–98 in the homologous pepscan also recognized the corresponding region of 07V063, but not the one of 08V204. Similarly, sera of 07V063-infected pigs that recognized position 87–98 of the homologous virus strain still reacted with the corresponding region of LV, but not with the one of 08V204. Sera derived from 08V204-infected pigs did not recognize any regions in GP4 of LV or 07V063 at all.
Antibodies against aa position 57–68 on GP4 of LV
(GVSAAQEKISFG), 07V063 (RVTAAQGRIYTR), and 08V204
(RTNTTQGKVPSQ), were used in single-replication virus-
neutralization tests on PAM with each of the respective
heterologous virus strains. LV-replication in PAM was not
reduced by antibodies directed against aa 57–68 of either
07V063 or 08V204 in any of the concentrations tested
(Fig. 6A). Similarly, replication of 07V063 (Fig. 6B) or 08V204
(Fig. 6C) in PAM was not reduced by antibodies against aa
57–68 of LV in any concentration. Infection with 07V063
and 08V204 was slightly but significantly reduced with high
concentrations of antibodies against aa 57–68 of the respec-
tive heterologous virus strain (Fig. 6B and C). However, this
reduction never reached 50%, and no dose-dependent re-
duction of infection was observed for these conditions.

Discussion

Two neutralizing epitopes have been identified on EU-
type PRRSV by the use of mAbs, one on GP5 and one on GP4

![Graph A](https://example.com)

**FIG. 2.** GP4 pepscan profiles of sera derived from LV-infected pigs. Sera collected at 44 d p.i. with LV were diluted 1:100 and used in a pepscan analysis with overlapping peptides covering GP4 of LV. OD (450 nm) values at each peptide were determined for both the test sample and a negative serum sample, and the OD for the test sample was expressed as the relative percentage of the negative control value for each peptide separately (percentage sample/negative). Signals were considered positive when the percentage sample/negative at a certain peptide was more than two times the mean percentage sample/negative over all peptides. Graph A represents a serum sample in which antibodies against peptides 14–16 were detected (core sequence GVSAAQEKISFG). Graph B represents a serum sample in which antibodies against peptides 14–16 as well as 22–23 (core sequence ITANVTDESILY) were detected.

![Graph B](https://example.com)

![Graph C](https://example.com)

**FIG. 3.** Reduction of LV replication in PAM by serum antibodies against peptides GVSAAQEKISFG (A) and ITANVTDESILY (B). A single replication virus-neutralization test was performed with a 1:2 dilution series (500–16 μg/mL) of epitope-specific serum antibodies, purified from polyclonal serum by peptide affinity chromatography. Protein A purified immunoglobulins of a PRRSV-negative pig were included as mock antibodies (open symbols). The number of infected cells for each antibody dilution was set relative to the mean number of infected cells for all mock conditions within one experiment. The means and standard deviations of three experiments were calculated and are given in the graphs. Statistically significant differences (*p < 0.01) were observed with GVSAAQEKISFG-specific antibodies, compared to mock antibodies for antibody concentrations between 500 and 63 μg/mL.
The neutralizing epitope on GP4 of the EU prototype LV strain has been shown to be immunogenic in pigs, but the kinetics of the antibody response against this or other epitopes on GP4 was never explored (34). In the current study, it was shown that naïve pigs produced high titers of GP4-specific antibodies upon infection with LV. Between 2 and 3 wk post-infection GP4-specific antibodies were directed against a linear region covering aa position 57–68, determining the epitope that was described earlier as a target for virus-neutralizing mAbs (7,28). Purified serum antibodies against peptides 57–68 clearly reduced single-virus replication in PAM in a concentration-dependent manner, showing that this epitope is a target for porcine virus-neutralizing antibodies as well. At the time antibodies against this epitope appeared, the sera, however, did not yet show neutralizing activity in a classical seroneutralization test on Marc-145.

![FIG. 4.](image) Alignment of the GP4 aa sequences of PRRSV strains LV, 07V063, and 08V204. The ORF4 sequences of PRRSV strain 07V063 and 08V204 were determined by PCR and cycle sequencing, and the deduced aa sequences were aligned to the GP4 sequence of LV. Dots represent residues that are identical to LV, and hyphens indicate gaps. Boxes indicate regions that are recognized by sera in pepscan analyses.

![FIG. 5.](image) Reduction of replication of 07V063 (A), or 08V204 (B), in PAM by serum antibodies against peptides RVTAAGRIYTR and RTNTTQGKVPSQ, respectively. A single replication virus-neutralization test with homologous virus was performed with a 1:2 dilution series (500–16 μg/mL) of epitope-specific serum antibodies, purified from polyclonal serum by peptide affinity chromatography. Protein A purified immunoglobulins of a PRRSV-negative pig were included as mock antibodies (open symbols). The number of infected cells for each antibody dilution was set relative to the mean number of infected cells for all mock conditions within one experiment. The means and standard deviations of three experiments were calculated and are given in the graphs. Statistically significant differences (*p < 0.01) were observed with RVTAAGRIYTR-specific antibodies, compared to mock antibodies, for antibody concentrations between 500 and 31 μg/mL in the test with virus strain 07V063. In the test with virus strain 08V204, statistically significant differences (*p < 0.01) were observed with RTNTTQGKVPSQ-specific antibodies, compared to mock antibodies, for antibody concentrations between 500 and 16 μg/mL.
cells. This can be explained by the lower sensitivity of this test, compared to the single-replication virus-neutralization test on PAM (10,54). However, no clear correlation was observed between the levels of GP4-specific antibodies and the levels of virus-neutralizing antibodies in sera, and it remains to be determined to what extent antibodies against GP4 contribute to the global neutralizing activity of polyclonal serum upon PRRSV-infection. Nevertheless, this study clearly shows that pigs are able to produce antibodies against a linear epitope on GP4 that reduce PRRSV replication in its natural host cell, the alveolar macrophage. Therefore, it is reasonable to expect that such antibodies, if present in sufficient amounts, will contribute to a significant reduction in virus replication in the host.

In addition to the neutralizing epitope, a second linear epitope at aa position 85–96 on GP4 of LV was recognized by some sera that were collected at later time points. However, antibodies against this less immunogenic epitope were not neutralizing at all.

The neutralizing epitope on GP4 of LV is located in a highly variable region, and it is not known thus far whether the corresponding regions of PRRSV strains other than LV are also targets for neutralizing antibodies (12,28). In the current study it was shown that similarly to LV, two Belgian PRRSV field isolates of EU genotype (07V063 and 08V204) strongly induce antibodies towards aa 57–68 of GP4, even though the aa sequences at this position are different. Serum antibodies against the corresponding peptides of each virus strain were able to reduce replication of the homologous virus in PAM. These data indicate that aa 57–68 on GP4 determines a highly immunogenic epitope that induces virus-neutralizing antibodies. In addition to LV, 07V063 and 08V204, also an LV-like vaccine strain, an EU-type field isolate, and even a NA-type PRRSV strain, have been shown to induce antibodies against the corresponding region on GP4 (9,33,34). The fact that this variable epitope on GP4 is highly immunogenic for a series of different PRRSV strains suggests that its immunogenicity is determined by the location rather than by the aa sequence.

It was previously shown that mAbs against the neutralizing epitope on GP4 of LV do not recognize or neutralize a series of European field isolates that differ in the corresponding region (28). Likewise, in the current study no dose-dependent cross-neutralization by serum antibodies against aa 57–68 was observed between LV, 07V063, and 08V204. Considering the fact that different virus strains strongly induce neutralizing antibodies against aa 57–68 on GP4, it is thus very likely that hypervariability in this region is the outcome of a high immunological selective pressure in vivo.

In agreement with this, Costers et al. recently showed that cultivation of LV in the continuous presence of mAbs against the neutralizing epitope on GP4 results in the selection of PRRSV variants that show aa changes in this epitope, making them insensitive to neutralization by the mAbs (7). ORF4 of PRRSV partially overlaps with ORF3, and the coding sequence for the neutralizing epitope on GP4 also determines a variable region in the C-terminal end of GP3 (39). The data presented here indicate that variability in this region is probably an additional effect of selective pressure exerted by antibodies against GP4 (32).

Neutralizing antibodies can interfere with viral infectivity in different ways (21,38). The antibodies may directly bind to
the viral ligand for a certain cellular receptor or entry mediator, inhibiting attachment, internalization, membrane fusion, or another post-entry step in infection. However, the variability in the neutralizing epitope on GP4, including non-conservative substitutions and even deletions, makes it improbable that this particular part of the protein is somehow involved in a crucial step in the virus replication cycle. More likely, neutralizing antibodies against aa 57–68 of GP4 block functional interactions of other, more conserved regions on the virus with their cellular counterparts by steric hindrance or by inducing conformational changes. If this is the case, the infectivity of virus quasispecies that show mutations in the neutralizing epitope will not be compromised, and viruses that escape neutralization by antibodies against this epitope will have a better chance of survival.

Several PRRSV proteins and epitopes have been associated with virus neutralization in the past on both EU- and NA-type strains. mAbs with neutralizing activity towards the virus have been characterized for their protein specificity and in some cases for their epitope specificity (3,28,35,36,48,51,53,56). This approach, however, does not offer any information about the way in which the natural host produces antibodies against these viral proteins and epitopes. Western blot analysis, phage display libraries, and ELISA with recombinant proteins and peptides, have been used to evaluate the specificity of the antibody response upon PRRSV infection in pigs (10,17,23,29,31,33,35,37,55). In some studies, statistical correlations were observed between serum reactivity against certain proteins or epitopes and the presence of virus-neutralizing antibodies, giving an indication about which viral domains may be the main inducers of virus-neutralizing antibodies (17,35,37). However, this approach does not directly show to what extent serum antibodies against particular epitopes are actually able to neutralize the virus. In the present study, the kinetics of the antibody response against linear epitopes on GP4 was determined, and antibodies against distinct epitopes were purified from polyclonal pig serum and directly used in virus-neutralization tests to determine their neutralizing capacity. This approach circumvents the limited availability of specific mAbs, allows the identification of in vivo relevant antibody targets, and makes it possible to directly examine to what extent porcine serum antibodies against each of these targets separately are able to neutralize the virus. In the current study, this has led to the discovery that a highly variable region in GP4 of EU-type PRRSV induces antibodies that neutralize homologous, but not heterologous, virus strains. The use of a similar approach for the study of the antibody response against other structural PRRSV proteins may lead to identification and characterization of more in vivo relevant antibody targets.

Acknowledgments

The authors want to acknowledge Chantal Vanmaercke, Carine Boone, Dries Helderweirt, and Geert Opsomer for excellent technical assistance. Merijn Vanhee was funded by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWTSB 071316). This work was funded by the EU (Seventh Framework Programme, Project Number 245141). All animal experiments were approved by the local ethical committee of the Faculty of Veterinary Medicine, Ghent University.

Author Disclosure Statement

No competing financial interests exist for any of the authors of this manuscript.

References

14. Duan X, Nauwynck Hj, and Pensaert MB: Virus quantification and identification of cellular targets in the lungs and lymphoid tissues of pigs at different time intervals after
15. Forsberg R, Storgaard T, Nielsen HS, et al.: The genetic diversity of European type PRRSV is similar to that of the North American type but is geographically skewed within Europe. Virology 2002;299:38–47.


Address correspondence to:
Dr. Hans Nauwynck
Laboratory of Virology
Department of Virology, Parasitology and Immunology
Faculty of Veterinary Medicine
Ghent University
Salisburylaan 133
9820 Merelbeke, Belgium

E-mail: hans.nauwynck@ugent.be

Received February 16, 2010; accepted April 19, 2010.